Ticker

Analyst Price Targets — PDS

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
March 2, 2026 3:41 pmSergey PigarevLoop Capital Markets$122.00$88.49StreetInsider Precision Drilling (PDS) PT Raised to $122 at Freedom Capital Markets
February 17, 2026 12:01 pm—Piper Sandler$105.00$87.35TheFly Precision Drilling price target raised to $105 from $81 at Piper Sandler
December 18, 2025 11:29 am—Piper Sandler$81.00$68.01TheFly Precision Drilling price target raised to $81 from $79 at Piper Sandler
October 28, 2025 10:32 amDerek PodhaizerPiper Sandler$79.00$59.05TheFly Precision Drilling price target raised to $79 from $74 at Piper Sandler
July 14, 2025 8:18 pmDerek PodhaizerPiper Sandler$72.00$49.78TheFly Precision Drilling initiated with an Overweight at Piper Sandler
May 6, 2024 7:37 amLuke LemoinePiper Sandler$101.00$71.12StreetInsider Precision Drilling (PDS) PT Raised to $101 at Piper Sandler
June 20, 2022 9:51 amIan MacphersonPiper Sandler$125.00$61.47Pulse 2.0 Precision Drilling (PDS) Stock: $125 Target And Overweight Rating
January 27, 2022 12:00 amJohn BereznickiCanaccord Genuity$47.74$41.72StreetInsider Canaccord Genuity Reiterates Hold Rating on Precision Drilling (PD:CN) (PDS)
January 7, 2022 12:00 amJames WestEvercore ISI$65.25$41.30TipRanks Contributor Precision Drilling (PDS) Received its Third Buy in a Row

Latest News for PDS

Should Value Investors Buy Precision Drilling (PDS) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Oct 16, 2026
PDS Biotechnology Targets Phase III Trial for PDS0301 in Metastatic Colorectal Cancer

PDS Biotechnology NASDAQ: PDSB outlined plans to advance its investigational immunocytokine PDS0301 into a Phase III study for heavily pretreated metastatic colorectal cancer with liver metastases, following discussions with the U.S. Food and Drug Administration and clinical findings from a National Cancer Institute-led study.

MarketBeat • Oct 15, 2026
Precision Drilling (TSE:PD) Shares Cross Above 50 Day Moving Average – What’s Next?

Shares of Precision Drilling Co. (TSE: PD - Get Free Report) (NYSE: PDS) passed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of C$120.13 and traded as high as C$123.16. Precision Drilling shares last traded at C$121.55, with a volume of 42,305 shares trading hands. Wall Street

Defense World • Oct 14, 2026
Comparing Precision Drilling (NYSE:PDS) and Solaris Energy Infrastructure (NYSE:SEI)

Solaris Energy Infrastructure (NYSE: SEI - Get Free Report) and Precision Drilling (NYSE: PDS - Get Free Report) are both energy companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Earnings and Valuation This table compares Solaris

Defense World • Oct 7, 2026
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases

PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a virtual key opinion leader (KOL) event featuring Jonathan M.

GlobeNewsWire • Oct 6, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for PDS.

No Senate trades found for PDS.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top